Research and Markets: ARBs Continue To Be The Only Class of Hypertension Treatments Unaffected by Generic Competition.DUBLIN, Ireland -- --Research and Markets (http://www.researchandmarkets.com/reports/c12999) has announced the addition of The Cardiovascular Market Outlook to 2009 to their offering. The Cardiovascular Market Outlook to 2009 provides detailed analysis on the major cardiovascular therapy areas and assesses competitive dynamics over the period 2004 to 2009. This report provides essential data, analysis and forecasts allowing you to position your products effectively, maximize market opportunities and increase cardiovascular revenues. The cardiovascular market is set to undergo a period of radical change, as today's blockbusters lose patent protection. The pharmaceutical industry is embracing innovative new technologies in order to provide the products of tomorrow, but with high costs and risks associated with the development of new medicines in this area, there will be fewer winners than losers in the future. Use this analysis to identify the forthcoming issues affecting cardiovascular markets, drugs, and companies and gain insight into the forces driving the most valuable sector of the pharmaceutical industry over the next 5 years. Why you should order your copy today - Assess the strength of leading players' cardiovascular portfolios and identify how they are positioning themselves to maintain and build franchise revenues. - Analyze the recent performance of drugs in each therapeutic class of the global cardiovascular market. - Quantify Quantify - A performance analysis tool from Pure Software. your products' market potential in the cardiovascular market by evaluating the patient base in different therapeutic classes. - Understand how the competitive landscape may be changed by the result of clinical trials such as EUROPA, EPHESUS, COMET and CHARM. - Identify the market potential and risks related to a range innovative future cardiovascular drugs currently in development, and assess their impact on the pipelines of the major players in the cardiovascular area. "The key driver of sales growth in the hypertension hypertension or high blood pressure, elevated blood pressure resulting from an increase in the amount of blood pumped by the heart or from increased resistance to the flow of blood through the small arterial blood vessels (arterioles). market is the ARB class, sales of which expanded by 27.7% to $8,971m in 2003. ARBs continue to be the only class of hypertension treatments that is unaffected by generic competition and can command a higher price premium than most rival products. Despite the presence of generic competition, alpha-blockers, beta-blockers and diuretics Diuretics Definition Diuretics are medicines that help reduce the amount of water in the body. Purpose Diuretics are used to treat the buildup of excess fluid in the body that occurs with some medical conditions such as congestive heart continued a pattern of modest growth in 2003, find out more with the help of this new report..." "The late to market status of Livalo has jeopardized rapid uptake uptake /up·take/ (up´tak) absorption and incorporation of a substance by living tissue. up·take n. in the major markets, and doubt now exists about whether this statin stat·in n. Any of a class of drugs that inhibit a key enzyme involved in the synthesis of cholesterol and promote receptor binding of LDL cholesterol, resulting in decreased levels of serum cholesterol. , which is relatively undifferentiated undifferentiated /un·dif·fer·en·ti·at·ed/ (un-dif?er-en´she-at-ed) anaplastic. un·dif·fer·en·ti·at·ed adj. Having no special structure or function; primitive; embryonic. from rivals, can create a niche for itself in the absence of major marketing backing in the US..." Key findings of the report - Pfizer's growth will be adversely affected by the continuing disappointing performance of recent launches Inspra and Caduet as well as the expiry of patents protecting Norvasc. - The net revenue growth of the cardiovascular franchises of the major players are set to suffer a net contraction in revenue growth, with Aventis and Pfizer performing particularly poorly over the forecast period 2004 to 2009. - Despite increasing prescribing volumes, earlier interventions and robust epidemiological epidemiological emanating from or pertaining to epidemiology. epidemiological associations the associative relationships between the frequency of occurrence of a disease and its determinants, its predisposing and precipitating growth, market growth across the major indications is set to fall over the forecast period. - Over the short-term, thrombosis thrombosis (thrŏmbō`sĭs), obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted. is set to be the major driver in the cardiovascular area, whilst heart failure has the most favourable dynamics of any indication for rapid market growth. - The growth of the dyslipidemia market is set to be further fuelled by statin adjunct adjunct (aj´ungkt), n a drug or other substance that serves a supplemental purpose in therapy. adjunct therapies, particularly Zetia, which is forecast to revive To renew. For example, revival is the act of renewing the legal force of a contract or debt, either by acknowledging it or by giving a new promise, when the contract or debt is no longer a sufficient foundation for a lawsuit because it is barred by the running of the Statute Merck's faltering cardiovascular franchise. "New launches Crestor and Livalo have little hope of attaining sales on the scale of Lipitor, which, following concerns about safety after the withdrawal of Baycol in 2001, has successfully distanced itself from dose dependent side-effects. Crestor, partly due to alleged negative marketing strategies from Pfizer, has failed to distance itself from these safety concerns, evident in its disappointing start following its launch in 2003..." The answers to your questions - How have recent major cardiovascular drug launches from Pfizer, AstraZeneca, Novartis, Merck, Aventis and BMS BMS abbr. Bachelor of Marine Science performed? - Which companies will become the key players in the cardiovascular market over the period 2004-2009? - Which pipeline products will be the growth drivers of the future? - Which products will be impacted by generic competitors over the period 2004-2009? - Which indications are forecast to have the highest levels of market potential in the forecast period? - How will the competitive landscape for hypertension, thrombosis, dyslipidemia and arrhythmia arrhythmia (ārĭth`mēə), disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of change by 2009? Company Profiles Pfizer Merck & Co Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Novartis AstraZeneca Aventis Drug profiles - Exanta - Crestor - Livalo - Caduet - Inspra - Zetia - AGI-1067 - Idraparinux - Noratak (nesiritide) - Sitaxsentan - SP100 - Pactimibe For more information visit http://www.researchandmarkets.com/reports/c12999 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion